Baird lowered the firm’s price target on Dyne Therapeutics (DYN) to $32 from $46 and keeps an Outperform rating on the shares. The firm updated its model following the swapping of the DYNE-101 endpoint from splicing to vHOT.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics: Strategic Advancements and Promising Clinical Data Drive Buy Rating
- Dyne Therapeutics’ DYNE-101 Gains Momentum with FDA Breakthrough Designation and Optimized Clinical Trials
- Dyne having vHOT as primary endpoint ‘encouraging,’ says H.C. Wainwright
- Positive Outlook for Dyne Therapeutics: Buy Rating Justified by Promising DYNE-101 Trial Results and Strategic Moves
- Dyne at ‘attractive entry point’ following pullback, says Chardan